Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Nafamostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.58 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.58 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.58 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.58 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.58 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.58 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.58 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.58 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.58 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.64 |
| ▸ | PRSS1 | P07477 | 10/20 | 0.58 |
| ▸ | F2 | P00734 | 8/20 | 0.58 |
| ▸ | KLKB1 | P03952 | 8/20 | 0.58 |
| ▸ | KLK1 | P06870 | 3/20 | 0.58 |
| ▸ | C1R | P00736 | 2/20 | 0.58 |
| ▸ | F10 | P00742 | 2/20 | 0.58 |
| ▸ | PLG | P00747 | 9/20 | 0.58 |
| ▸ | F12 | P00748 | 7/20 | 0.58 |
| ▸ | HGFAC | Q04756 | 2/20 | 0.58 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nafamostat SCHEMBL29832433 | 0.95 | FTO (0.70) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL1568755 | 0.95 | FTO (0.70) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL564665 | 0.95 | FTO (0.70) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL29429445 | 0.94 | PRSS1 (0.64) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL29429443 | 0.94 | PRSS1 (0.64) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL135503 | 0.94 | PRSS1 (0.64) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL16069975 | 0.94 | PRSS1 (0.64) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL3302794 | 0.93 | PRSS1 (0.63) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL7345508 | 0.91 | PRSS1 (0.62) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL7051240 | 0.88 | PLAU (0.58) | FTOPRSS1F2KLKB1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210177789-A1 | ADMINISTRATION OF SERINE PROTEASE INHIBITORS TO THE STOMACH | LEADING BIOSCIENCES INC (US) | 2021-06-17 | — | — | US | claimed |
| US-10137100-B2 | Administration of serine protease inhibitors to the stomach | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-11-27 | — | — | US | claimed |
| US-20180153834-A1 | TREATMENT OF CONDITIONS RELATED TO SHOCK | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-06-07 | — | — | US | claimed |
| US-20170119710-A1 | TREATMENT OF CONDITIONS RELATED TO SHOCK | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-05-04 | — | — | US | claimed |
| US-9272034-B2 | Treatment of conditions related to shock | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-03-01 | — | — | US | claimed |
| EP-3677261-B1 | ADMINISTRATION OF SERINE PROTEASE INHIBITORS TO THE STOMACH | INFLAMMAGEN (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11439611-B2 | Administration of serine protease inhibitors to the stomach | Leading BioSciences, Inc. (US) | 2022-09-13 | — | — | US | disclosed |
| US-20210177789-A1 | ADMINISTRATION OF SERINE PROTEASE INHIBITORS TO THE STOMACH | LEADING BIOSCIENCES INC (US) | 2021-06-17 | — | — | US | disclosed |
| US-10772861-B2 | Administration of serine protease inhibitors to the stomach | Leading Biosciences, LLC (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200246291-A9 | ADMINISTRATION OF SERINE PROTEASE INHIBITORS TO THE STOMACH | INFLAMMAGEN, LLC (US) | 2020-08-06 | — | — | US | disclosed |
| EP-3677261-A1 | ADMINISTRATION OF SERINE PROTEASE INHIBITORS TO THE STOMACH | Inflammagen (US) | 2020-07-08 | — | — | EP | disclosed |
| US-20190175532-A1 | ADMINISTRATION OF SERINE PROTEASE INHIBITORS TO THE STOMACH | INFLAMMAGEN, LLC (US) | 2019-06-13 | — | — | US | disclosed |
| US-9272034-B2 | Treatment of conditions related to shock | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-03-01 | — | — | US | disclosed |
| US-20130310325-A1 | ADMINISTRATION OF SERINE PROTEASE INHIBITORS TO THE STOMACH | Leading BioSciences, Inc. | 2013-11-21 | — | — | US | disclosed |
| US-8541371-B2 | Treatment of conditions related to cecal ligation shock | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2624823-A2 | ADMINISTRATION OF SERINE PROTEASE INHIBITORS TO THE STOMACH | Inflammagen (US) | 2013-08-14 | — | — | EP | disclosed |
| WO-2012040595-A2 | ADMINISTRATION OF SERINE PROTEASE INHIBITORS TO THE STOMACH | INFLAMMAGEN (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20080195024-A1 | Treating Disorders Associated with Inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-08-14 | — | — | US | disclosed |
| US-6534283-B1 | Method for treatment and prevention of physiological shock | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-03-18 | — | — | US | disclosed |
| WO-2001037854-A1 | METHOD FOR TREATMENT AND PREVENTION OF PHYSIOLOGICAL SHOCK | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-05-31 | — | — | WO | disclosed |